Tema Etfs LLC Has $381,000 Holdings in Arrowhead Pharmaceuticals, Inc. $ARWR

Key Points

• Tema Etfs LLC reduced its stake in Arrowhead Pharmaceuticals by 51.4% during the first quarter, bringing its holdings down to 29,893 shares valued at approximately $381,000.
• Despite the decrease from Tema Etfs, several other institutional investors, including Rafferty Asset Management, increased their stakes, with Rafferty's holdings growing by 39.3% to 192,791 shares.
• Arrowhead Pharmaceuticals reported earnings per share of (1.26), missing consensus estimates, and a revenue of $27.77 million for the quarter, compared to an expected $29.01 million.

Tema Etfs LLC lessened its stake in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 51.4% during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 29,893 shares of the biotechnology company's stock after selling 31,610 shares during the period. Tema Etfs LLC's holdings in Arrowhead Pharmaceuticals were worth $381,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the business. GAMMA Investing LLC raised its position in Arrowhead Pharmaceuticals by 297.6% in the first quarter. GAMMA Investing LLC now owns 2,175 shares of the biotechnology company's stock valued at $28,000 after purchasing an additional 1,628 shares during the period. GF Fund Management CO. LTD. purchased a new stake in shares of Arrowhead Pharmaceuticals in the 4th quarter valued at $49,000. CWM LLC increased its stake in Arrowhead Pharmaceuticals by 134.3% during the first quarter. CWM LLC now owns 4,401 shares of the biotechnology company's stock worth $56,000 after purchasing an additional 2,523 shares during the period. KBC Group NV increased its stake in Arrowhead Pharmaceuticals by 40.8% during the first quarter. KBC Group NV now owns 7,356 shares of the biotechnology company's stock worth $94,000 after purchasing an additional 2,132 shares during the period. Finally, XTX Topco Ltd purchased a new stake in Arrowhead Pharmaceuticals during the first quarter worth about $133,000. Hedge funds and other institutional investors own 62.61% of the company's stock.

Arrowhead Pharmaceuticals Stock Performance

Shares of NASDAQ:ARWR traded up $1.16 during trading on Wednesday, hitting $26.84. 2,044,726 shares of the company traded hands, compared to its average volume of 1,991,138. The company has a quick ratio of 4.87, a current ratio of 4.87 and a debt-to-equity ratio of 0.39. Arrowhead Pharmaceuticals, Inc. has a one year low of $9.57 and a one year high of $27.48. The business's fifty day moving average is $18.03 and its 200-day moving average is $16.06. The stock has a market capitalization of $3.71 billion, a price-to-earnings ratio of -20.97 and a beta of 1.00.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The biotechnology company reported ($1.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.94) by ($0.32). The firm had revenue of $27.77 million during the quarter, compared to the consensus estimate of $29.01 million. During the same period last year, the firm posted ($1.38) earnings per share. As a group, equities analysts predict that Arrowhead Pharmaceuticals, Inc. will post -2.42 earnings per share for the current fiscal year.

Insider Buying and Selling at Arrowhead Pharmaceuticals

In other Arrowhead Pharmaceuticals news, insider James C. Hamilton sold 9,389 shares of the business's stock in a transaction dated Friday, August 15th. The stock was sold at an average price of $20.00, for a total value of $187,780.00. Following the completion of the sale, the insider owned 262,122 shares of the company's stock, valued at $5,242,440. The trade was a 3.46% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 4.30% of the stock is owned by corporate insiders.

Analyst Ratings Changes

ARWR has been the topic of several recent analyst reports. HC Wainwright reissued a "buy" rating and issued a $80.00 target price on shares of Arrowhead Pharmaceuticals in a report on Tuesday. Wall Street Zen lowered shares of Arrowhead Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Friday, July 18th. Citigroup decreased their price objective on shares of Arrowhead Pharmaceuticals from $21.00 to $17.00 and set a "neutral" rating on the stock in a report on Tuesday, May 13th. Royal Bank Of Canada decreased their target price on Arrowhead Pharmaceuticals from $40.00 to $38.00 and set an "outperform" rating on the stock in a research report on Friday, August 8th. Finally, TD Cowen upgraded shares of Arrowhead Pharmaceuticals to a "strong-buy" rating in a research report on Monday, July 28th. Two equities research analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating and two have given a Hold rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus price target of $43.14.

Arrowhead Pharmaceuticals Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.